Wilmslow, United Kingdom

Arthur Rushton

This inventor holds 1 USPTO granted patent. Top assignee: Protherics Medicines Development Limited. Active years: 2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arthur Rushton. Retrieved from https://idiyas.com/inventor/arthur-rushton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Introduction

Arthur Rushton is an accomplished inventor based in Wilmslow, GB. He is recognized for his significant contributions to the field of pharmacology, particularly with his innovative work on angiotensin derivatives.

Latest Patents

Arthur Rushton holds a patent for an angiotensin derivative. This invention consists of at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety, which is designed for therapeutic and prophylactic applications concerning conditions associated with the renin-activated angiotensin system. This groundbreaking work highlights his expertise and commitment to advancing medical treatments.

Career Highlights

Arthur is part of Protherics Medicines Development Limited, a company focused on developing new medicines and therapies. His role as an inventor at this organization underscores his dedication to innovation, particularly in the pharmaceutical sector.

Collaborations

Throughout his career, Arthur Rushton has collaborated with notable colleagues, including James Francis Glover and Phillip John Morgan. These partnerships reflect a shared mission to contribute to advancements in medicine and improve patient outcomes.

Conclusion

In summary, Arthur Rushton is a notable inventor whose work on angiotensin derivatives illustrates his valuable contributions to medical science. His innovative approaches and collaborative spirit enhance the fundamental understanding of treatment mechanisms associated with the renin-activated angiotensin system, paving the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…